The U.S. Food and Drug Administration (FDA) has granted Yisheng Biopharma orphan drug designation (ODD) for its lead immuno-oncology candidate, YS-ON-001, for the treatment of pancreatic cancer.     To date, the FDA has granted YS-ON-001 two ODDs for the treatment of pancreatic cancer and hepatocellular carcinoma.   YS-ON-001 is a clinical-stage immuno-oncology biologic product with unique immunomodulating mechanism and broad spectrum of anti-tumor activity.   Dr. Hui Shao, the p...